Key statistics
As of last trade SAGE Therapeutics Inc (SG7:FRA) traded at 4.59, 2.57% above its 52-week low of 4.47, set on Nov 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.59 |
---|---|
High | 4.59 |
Low | 4.59 |
Bid | 4.81 |
Offer | 4.84 |
Previous close | 4.74 |
Average volume | 33.33 |
---|---|
Shares outstanding | 61.17m |
Free float | 53.88m |
P/E (TTM) | -- |
Market cap | 296.69m USD |
EPS (TTM) | -5.58 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 07:47 GMT.
More ▼
Press releases
- Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease
- Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates
- Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
- Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
- Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer’s Disease
- Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
More ▼